A new era of personalised cancer treatments - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

A new era of personalised cancer treatments

As incidence rises, breakthroughs in oncology show the value of research funding
00:00

{"text":[[{"start":9.17,"text":"Good news is flowing from the world’s cancer labs. "},{"start":12.187000000000001,"text":"Researchers are reporting encouraging clinical trial results for a diversity of novel treatments, including individualised cancer vaccines, as well as new diagnostic techniques. "},{"start":21.692,"text":"Various forms of immunotherapy — adapting the patient’s immune system to destroy cancer cells — are proving remarkably successful at extending survival times of some people with refractory tumours. "}],[{"start":32.53,"text":"One reason for the rapid progress is that cancer research has been well funded by industry, governments and charities in comparison with other diseases. "},{"start":40.472,"text":"Almost 40 per cent of all pharmaceutical R&D investment is directed at clinical oncology — making it the leading field for precision medicine, with diagnostics and drugs tailored to the individual characteristics of patients. "}],[{"start":52.510000000000005,"text":"This encouraging lesson about the productivity of research funding has not been lost on scientists working on different diseases, such as dementia and infections, where there is much unmet medical need but relatively less investment. "},{"start":64.302,"text":"They are right to point to cancer as an example of what can be achieved with more R&D resources. "}],[{"start":70.25,"text":"Moving cancer research breakthroughs rapidly into regular clinical practice will require agile regulators and responsive healthcare providers. "},{"start":77.742,"text":"They must provide not only appropriate treatment facilities, but diagnostic services to detect tumours as early as possible when chances of a cure are highest. "}],[{"start":87.03,"text":"The new wave of personalised treatments will be expensive when first introduced; immunotherapies often cost more than $100,000 per patient. "},{"start":95.259,"text":"Pharma companies will inevitably come under pressure to cut what their critics may portray as exorbitant pricing. "},{"start":100.952,"text":"While drug prices must be subject to some control, the industry’s return on investment should remain high enough to maintain its large, productive cancer research effort. "},{"start":109.644,"text":"Costs of new medical technologies do come down over time as they are applied more extensively. "}],[{"start":115.5,"text":"Faster diagnosis and better treatments are needed more than ever, as the incidence of cancer continues to rise globally. "},{"start":121.94200000000001,"text":"Disturbingly, cases are growing most rapidly among younger people, for reasons that scientists are only just beginning to understand — and which require urgent investigation. "},{"start":131.272,"text":"Cancer rates in 25- to 49-year-olds increased by 24 per cent since 1995, according to the charity Cancer Research UK. "},{"start":139.727,"text":"Although cancer remains largely an affliction of old age, and under-50s still account for no more than 10 per cent of all patients, they represent a much larger proportion of years of healthy life lost to the disease. "}],[{"start":150.98,"text":"Experts believe the rapid increase in obesity in recent decades is one factor driving the growth of tumours such as breast and colorectal cancer among the young. "},{"start":159.384,"text":"Data presented at the recent American Society of Clinical Oncology conference in Chicago suggests that taking the popular weight-loss drugs Ozempic and Wegovy would reduce the risk of developing many common tumours — though, as public health campaigners point out, it would be preferable to tackle obesity by changing people’s diets rather than by medication. "},{"start":177.10199999999998,"text":"Beyond obesity, scientists are looking for carcinogenic signals among the many environmental and lifestyle changes that have taken place over recent decades. "}],[{"start":185.67,"text":"As the disease becomes more prevalent, people are living for longer on average after diagnosis, though progress is currently slow. "},{"start":192.69899999999998,"text":"Human biology means that cancer will always be with us. "},{"start":195.94199999999998,"text":"But the new diagnostic tools and treatments emerging from the world’s labs promise to accelerate the extension of survival time — and make oncology a shining example of the value of biomedical research spending. "}],[{"start":206.75,"text":""}]],"url":"https://creatives.ftacademy.cn/album/158108-1717832601.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

秘密对冲基金为激进卖空者提供资金

当华尔街自诩为金融侦探的人对目标公司发出指控时,这些沉默的合作伙伴就会从中获利。

芝加哥的唐•威尔逊是金融界最聪明的人吗?

从雷曼兄弟破产后的清理工作到早期对比特币的押注,DRW已成为行业巨头。

如何规避关税的指南

在特朗普准备重返白宫之际,或许是时候翻开那本大豆食谱了。

角斗士II:比第一集更血腥、更疯狂、更有趣

雷德利•斯科特在一部由保罗•梅斯卡尔、佩德罗•帕斯卡和丹泽尔•华盛顿主演的趾高气扬的续集中大肆宣扬野蛮行径。

人工智能狂潮让老牌美国电信公司躲过灭亡的命运

大型科技交易可能为Lumen及其垂死的同行提供了生命线。

为什么政府在解决问题方面如此糟糕?

世界各地的政客似乎注定要重蹈覆辙。还有另一种方法。
设置字号×
最小
较小
默认
较大
最大
分享×